Table of Contents
MORRISTOWN, N.J. — Watson Pharmaceuticals Inc. has promoted David Buchen to executive vice president, general counsel and secretary and R. Todd Joyce to executive vice president and chief financial officer.
Watson said Wednesday that Buchen and Joyce, both previously senior vice presidents in those roles, will continue to report to Paul Bisaro, president and chief executive officer.
"These promotions not only recognize the substantial individual contributions David and Todd have made to Watson’s ongoing success, but also the significant achievements made by both in building the teams that support our Company’s global growth," stated Bisaro.
"With the increasing complexity of our global portfolio — generics, brands and biologics — our international legal team has been increasingly called upon under David’s leadership to support a broad array of competitive, compliance and intellectual property legal activities," the CEO explained. "Todd and his team have ensured the seamless integration of our global finance operations following the Arrow acquisition and demonstrated the leadership required to manage our global finances, which have allowed us to deliver on our financial commitments while maintaining our capacity for continued growth and expansion. Both promotions are well-deserved and reflect the importance of these functions and the role of these two leaders in our success."
Joyce was appointed senior vice president and chief financial officer of Watson in October 2009. He joined the company in 1997 as corporate controller and was named vice president, corporate controller and treasurer in 2001. During the periods October 2006 to November 2007 and July 2009 to October 2009, Joyce served as interim principal financial officer.
Buchen has been senior vice president, general counsel and secretary since November 2002. From November 1998 to November 2002, he served in a number of positions with increasing responsibility.
